<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155219</url>
  </required_header>
  <id_info>
    <org_study_id>LTG1030-PIV-12/07</org_study_id>
    <nct_id>NCT01155219</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.</brief_title>
  <acronym>T1030</acronym>
  <official_title>Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of
      Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially
      treated and stabilised by monotherapy of Xalatan® with ocular objective signs of intolerance
      to prostaglandin eye drops.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives are to compare the safety and the efficacy of Geltim LP® 1mg/g eye
      drops versus Xalatan® eye drops with respect to:

      The assessment of the ocular tolerance:

        -  Ocular symptoms

        -  Objective ocular signs.

      The maintain of the IOP efficient lowering effect. Comparison between the 2 study products
      of the mean basal IOP after a 12 weeks treatment period (84 days ±7).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular Tolerance</measure>
    <time_frame>Day 84</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response defined as a combination of satisfactory or acceptable effect on IOP and a reduction of at least 20% of the total tolerance score in the worse eye.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Geltim LP®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalatan®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geltim LP 1 mg/g</intervention_name>
    <description>one drop in the conjunctival sac of each eye in the morning (84 days).</description>
    <arm_group_label>Geltim LP®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>one drop in the conjunctival sac of each eye in the morning (84 days).</description>
    <arm_group_label>Xalatan®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Association of the 4 following criteria:

               1. - Bilateral primary open angle glaucoma or bilateral ocular hypertension already
                  treated and controlled by mono-therapy of Xalatan® (1drop per day),

               2. - With local intolerance signs.

        Exclusion Criteria:

          -  Presence of severe objective ocular sign.

          -  Any ocular hypertension other than primary ocular hypertension or primary chronic
             open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).

          -  Absolute defect in the ten degrees central point of the visual field.

          -  Best far corrected visual acuity ≤ 1/10.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>October 24, 2014</lastchanged_date>
  <firstreceived_date>June 30, 2010</firstreceived_date>
  <firstreceived_results_date>October 24, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bilateral Glaucoma</keyword>
  <keyword>Bilateral ocular hypertension</keyword>
  <keyword>Bilateral primary open angle glaucoma</keyword>
  <keyword>Bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day)</keyword>
  <keyword>With local intolerance signs in at least one eye</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Geltim LP®</title>
          <description>Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
Geltim LP 1 mg/g: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
        </group>
        <group group_id="P2">
          <title>Xalatan®</title>
          <description>Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
Xalatan: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-medical reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Geltim LP®</title>
          <description>Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
Geltim LP 1 mg/g: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
        </group>
        <group group_id="B2">
          <title>Xalatan®</title>
          <description>Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
Xalatan: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="73"/>
                <measurement group_id="B3" value="150"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65.94" spread="11.79"/>
                <measurement group_id="B2" value="64.86" spread="11.62"/>
                <measurement group_id="B3" value="65.41" spread="11.68"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="99"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="73"/>
                <measurement group_id="B3" value="150"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Tolerance</title>
        <description>Response defined as a combination of satisfactory or acceptable effect on IOP and a reduction of at least 20% of the total tolerance score in the worse eye.</description>
        <time_frame>Day 84</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Geltim LP®</title>
            <description>Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
Geltim LP 1 mg/g: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan®</title>
            <description>Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
Xalatan: one drop in the conjunctival sac of each eye in the morning (84 days).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Tolerance</title>
            <description>Response defined as a combination of satisfactory or acceptable effect on IOP and a reduction of at least 20% of the total tolerance score in the worse eye.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Geltim LP®</title>
          <description>Geltim LP® 1 mg/g (0.1 % unpreserved timolol maleate gel)
One drop in the conjunctival sac of each eye in the morning</description>
        </group>
        <group group_id="E2">
          <title>Xalatan®</title>
          <description>Latanoprost
One drop in the conjunctival sac of each eye in the evening</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pascale Pouliquen</name_or_title>
      <organization>Laboratoires Thea</organization>
      <phone>0473981436</phone>
      <email>p.pouliquen@laboratoires-thea.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
